Patent US4474756A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4474756A Expired / Lapsed US ⏱️ 0.0 years remaining

Process for the production of anti-human protein antibody

Assignee: Hayashibara Seibutsu Kagaku Kenkyujo KK
•
Filing: 1982-01-04
•
Granted: 1984-10-02
•
Expires: 2002-01-04
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The present invention relates to a process for the production of anti-human protein antibody, comprising induction of the antibody production in non-human warm-blooded animal cells capable of producing said antibody by injecting into a non-human warm-blooded animal a human protein-saccharide conjugate, obtained by covalent attachment of a human protein with a saccharide, and harvesting the resulting anti-human protein antibody. The antibody, prepared according to the invention, contains an extremely higher amount of immunoglobulin G than that obtained by conventional method while it contains slight or substantially no immunoglobulin E. Therefore, the antibody can be used advantageously for diagnostic, prophylactic or therapeutic administration in the prevention and treatment of human diseases.

Inventors

  • 👤 Masakazu Mitsuhashi
  • 👤 Shunsaku Koyama

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-04 12:44
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; A; A61; A61K; A61K39/00; A61K39/395; A61K39/385; A61K47/00; A61K47/50; A61K47/51; A61K47/56; A61K47/61; A61K2039/60; A61K2039/6087; Y; Y10; Y10S; Y10S530/00; Y10S530/806; Y10S530/827; Y10S530/829; Y10S530/83; Y10S530/862

Claims Analysis

Total Claims: 9
Claim 1
Independent Claim 130 words
In a process for producing anti-human protein antibody, which comprises administering a human protein to a non-human warm-blooded animal as an antigen, feeding the animal for a period sufficient to accumulate a substantial amount of anti-human protein antibody in the serum, and harvesting the resultant anti-human protein antibody from the serum, the improvement, whereby the production of immunoglobulin G antibody is extremely enhanced, and whereby the formation of undesirable immunoglobulin E antibody is completely suppressed or diminished, wherein said human protein which is administered to the non-human warm-blooded animal is a human protein-saccharaide conjugate comprising an antigenic human protein covalently attached to a member selected from the group consisting of pullulan, elsinan, their partial hydrolysates and mixtures thereof, having an average molecular weight in the range from 1,000 to 10,000,000.
Claim 2
Dependent Claim 130 words
In a process for producing anti-human protein antibody, which comprises administering a human protein to a non-human warm-blooded animal as an antigen, feeding the animal for a period sufficient to accumulate a substantial amount of anti-human protein antibody in the serum, and harvesting the resultant anti-human protein antibody from the serum, the improvement, whereby the production of immunoglobulin G antibody is extremely enhanced, and whereby the formation of undesirable immunoglobulin E antibody is completely suppressed or diminished, wherein said human protein which is administered to the non-human warm-blooded animal is a human protein-saccharaide conjugate comprising an antigenic human protein covalently attached to a member selected from the group consisting of pullulan, elsinan, their partial hydrolysates and mixtures thereof, having an average molecular weight in the range from 1,000 to 10,000,000.
Claim 3
Dependent Claim 32 words
A process as set forth in claim 1, wherein said human protein is a member selected from the group consisting of human interferon, human urokinase, human lymphoblastoid protein and human chorionic gonadotropin.
Claim 4
Dependent Claim 26 words
A process as set forth in claim 1, wherein said covalent attachment is effected by a method which is diazo, peptide, alkylation, cross-linking or disulfide method.
Claim 5
Dependent Claim 41 words
A human protein-saccharide conjugate consisting of an antigenic human protein covalently attached to a member selected from the group consisting of pullulan, elsinan, their partial hydrolysates and mixtures thereof, having an average molecular weight in the range from 1,000 to 10,000,000.
Claim 6
Dependent Claim 41 words
A human protein-saccharide conjugate consisting of an antigenic human protein covalently attached to a member selected from the group consisting of pullulan, elsinan, their partial hydrolysates and mixtures thereof, having an average molecular weight in the range from 1,000 to 10,000,000.
Claim 7
Dependent Claim 33 words
A human protein-saccharide conjugate in accordance with claim 4, wherein said human protein is a member selected from the group consisting of human interferon, human urokinase, human lymphoblastoid protein and human chorionic gonadotropin.
Claim 8
Dependent Claim 27 words
A human protein-saccharide conjugate in accordance with claim 4, wherein said covalent attachment is effected by a method which is diazo, peptide, alkylation, cross-linking or disulfide method.
Claim 9
Dependent Claim 23 words
An anti-human protein antibody preparation high in immunoglobulin G component and low in immunoglobulin E component produced by the process of claim 1.

References Cited (Backward Citations)

US3639213A Cited
US4185090A Cited
US4041152A Cited
US4238473A Cited
US4196265A Cited
US4172124A Cited
US4364935A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1987-10-02 1988-04-02 1988-10-02 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1991-10-02 1992-04-02 1992-10-02 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1995-10-02 1996-04-02 1996-10-02 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag